Anifrolumab and the cytopenias of lupus: a third normalise fully

Design

retrospective multicentre observational cohort, seven European countries

Population

47 adults with SLE and at least one disease-related haematologic abnormality at anifrolumab initiation, 91.5% female

Primary outcome

complete haematologic response, defined as normalisation of every baseline abnormality

Effect

17/47 (36.2%) overall; 8/43 (18.6%) at 3 months and 14/46 (30.4%) cumulatively within 6 months

Seven European centres pooled 47 adults with systemic lupus erythematosus (SLE) who had at least one disease-related haematologic abnormality when anifrolumab was started. In 21 the drug was started for the cytopenia itself; in 26 it was started for something else and the abnormality was present at baseline. Complete haematologic response was defined strictly, as normalisation of every affected lineage.

About a third reached that bar overall, and most of the movement happened early: 18.6% by three months, 30.4% cumulatively by six. Haemoglobin, leucocyte and lymphocyte counts improved significantly by month three; platelets rose but not significantly. Response rates were similar whether or not the drug had been started for the cytopenia. Higher baseline CRP, ESR and SLE-DAS were associated with failing to reach complete response.

This is a retrospective series of 47 patients with no control group, so it cannot separate the drug's effect from concurrent glucocorticoid or from regression to the mean. What it usefully supplies is a timeframe and a realistic expectation: if you are using anifrolumab in a patient who also has anaemia or leucopenia, the blood count is worth rechecking at three months, and a partial response involving one lineage is the commoner outcome. It is not evidence for using anifrolumab as a treatment for lupus cytopenia on its own.

• Record which lineages are affected before starting, so response can be judged lineage by lineage
• Recheck the full blood count at three months — most of the change had happened by then
• Expect platelets to move least; thrombocytopenia should not be the reason for choosing the drug
• High CRP, ESR or SLE-DAS at baseline was associated with a lower chance of full normalisation
• A quarter stopped the drug during follow-up — review tolerability actively, not only at flares

The statistics, in plain English

With 47 patients, a response rate of 36.2% carries a wide confidence interval either side, so the true figure could plausibly sit anywhere from roughly a fifth to a half. Denominators shift between timepoints (43 at three months, 46 within six) because follow-up was incomplete, which inflates apparent response slightly. The association between raised baseline CRP or ESR and non-response comes from a small number of comparisons in a small sample and should be read as hypothesis-generating.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.